The importance of pharmacoepidemiology in pregnancy-implications for safety

References

• Stadler J. [Developmental and reproductive toxicology: interest and interpretation]. Therapie. févr. 2014;69(1):25–30.
   PubMed Web of Science ®Google Scholar
• Pregnancy: Clinical Trials [Internet]. [cité mai 2017 24]. Disponible sur: https://www.nichd.nih.gov/health/topics/pregnancy/clinicaltrials/Pages/default.aspx
   Google Scholar
• European Medicines Agency - Pharmacovigilance - Good pharmacovigilance practices [Internet]. [cité mai 2017 24]. Disponible sur: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp
   Google Scholar
• Damase-Michel C, Pichereau J, Pathak A, et al. Perception of teratogenic and foetotoxic risk by health professionals: a survey in Midi-Pyrenees area. Pharm Pract. 2008 janv;6(1):15–19.
   PubMedGoogle Scholar
• Herd P, Higgins J, Sicinski K, et al. The implications of unintended pregnancies for mental health in later life. Am J Public Health. 2016 mars;106(3):421–429.
   PubMed Web of Science ®Google Scholar
• Moreau C, Bohet A. Frequency and correlates of unintended pregnancy risk perceptions. Contraception. Août 2016;94(2):152–159.
   PubMed Web of Science ®Google Scholar
• Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet Lond Engl. 23 Oct. 1982;2(8304):937.
   PubMed Web of Science ®Google Scholar
• Damase-Michel C, Vié C, Lacroix I, et al. Drug counselling in pregnancy: an opinion survey of French community pharmacists. Pharmacoepidemiol Drug Saf. Oct 2004;13(10):711–715.
   PubMed Web of Science ®Google Scholar
• Damase-Michel C, Lapeyre-Mestre M, Moly C, et al. [Drug use during pregnancy: survey in 250 women consulting at a university hospital center]. J Gynecol Obstet Biol Reprod (Paris). févr. 2000;29(1):77–85.
   PubMedGoogle Scholar
• Lacroix I, Damase-Michel C, Lapeyre-Mestre M, et al. Prescription of drugs during pregnancy in France. Lancet Lond Engl. 18 nov. 2000;356(9243):1735–1736.
   PubMed Web of Science ®Google Scholar
• ENCePP Home Page [Internet]. [cité 2017 mai 24]. Disponible sur: http://www.encepp.eu/
   Google Scholar
• Mcbride WG. Thalidomide and congenital abnormalities. The Lancet. 1961 16 déc;278(7216):1358.
   Google Scholar
• Lenz W, Pfeiffer RA, Kosenow W, et al. Thalidomide and congenital abnormalities. The Lancet. 1962 janv 6;279(7219):45–46.
   Google Scholar
• Anderka MT, Lin AE, Abuelo DN, et al. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. juin 2009;149A(6):1241–1248.
   PubMed Web of Science ®Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Philadelphia, Lippincott Williams & Wilkins; 2012; p. 1728.
   Google Scholar
• Are ACE inhibitors safe in pregnancy? Lancet Lond Engl. 1989 26 août;2(8661):482–483.
   Google Scholar
• Lindquist M. VigiBase, the WHO global icsr database system: basic Facts. Drug Inf J. 2008 sept 1;42(5):409–419.
   Web of Science ®Google Scholar
• Vial T, Gouraud A, Bernard N. [Terappel: description of a computerised database and examples of studies]. Therapie. févr. 2014;69(1):31–38.
   PubMed Web of Science ®Google Scholar
• Elefant E, Vauzelle C, Beghin D. [Centre de référence sur les agents tératogènes (CRAT): a pioneer center]. Therapie. févr. 2014;69(1):39–45.
   PubMed Web of Science ®Google Scholar
• Leen-Mitchell M, Martinez L, Gallegos S, et al. Mini-review: history of organized teratology information services in North America. Teratology. Avr 2000;61(4):314–317.
   PubMedGoogle Scholar
• ENTIS [Internet]. [2017 mai 24]. Disponible sur: https://www.entis-org.eu/
   Google Scholar
• Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy–15 years experience of ENTIS. Reprod Toxicol. 2005;20(3):331–343.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Chambers C, Wacker E, Network of French Pharmacovigilance Centers, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol Hoboken NJ. 2014 mai;66(5):1101–1110.
   PubMed Web of Science ®Google Scholar
• Schaefer C. Drug safety in pregnancy: utopia or achievable prospect? Risk information, risk research and advocacy in Teratology Information Services. Congenit Anom. Mars 2011;51(1):6–11.
   PubMed Web of Science ®Google Scholar
• De Graaf JP, Steegers EAP, Bonsel GJ. Inequalities in perinatal and maternal health. Curr Opin Obstet Gynecol Avr 2013;25(2):98–108.
   PubMed Web of Science ®Google Scholar
• Beck E, Lechner A, Schaefer C. Who seeks Teratology Information Service’s advice? Assessing the risk of selection bias in observational cohort studies on drug risks in pregnancy. Reprod Toxicol Elmsford N. janv. 2017;67:79–84.
   PubMed Web of Science ®Google Scholar
• Vannappagari V, Albano JD, Koram N, et al. Prenatal exposure to zidovudine and risk for ventricular septal defects and congenital heart defects: data from the Antiretroviral Pregnancy Registry. Eur J Obstet Gynecol Reprod Biol. févr. 2016;197:6–10.
   PubMed Web of Science ®Google Scholar
• EUROCAT [Internet]. [cité 2017 mai 24]. Disponible sur: http://www.eurocat-network.eu/aboutus/whatiseurocat/whatiseurocat
   Google Scholar
• Yoon PW, Rasmussen SA, Lynberg MC, et al. The National Birth Defects Prevention Study. Public Health Rep Wash DC 1974. 2001;116(Suppl 1):32–40.
   PubMed Web of Science ®Google Scholar
• Czeizel AE, Métneki J, Béres J. 50 years of the Hungarian Congenital Abnormality Registry. Congenit Anom. févr. 2014;54(1):22–29.
   PubMed Web of Science ®Google Scholar
• Walley T, Mantgani A. The UK General Practice Research Database. Lancet Lond Engl. 1997 oct 11;350(9084):1097–1099.
   PubMed Web of Science ®Google Scholar
• Furu K, Wettermark B, Andersen M, et al. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010 févr;106(2):86–94.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659–667.
   PubMed Web of Science ®Google Scholar
• Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol. 2009 avr 14;65(8):839–846.
   PubMed Web of Science ®Google Scholar
• Damase-Michel C, Lacroix I, Hurault-Delarue C, et al. les partenaires d’EFEMERIS. [Drug in Pregnancy: studies in the French Database EFEMERIS]. Therapie. 2014 févr;69(1):91–100.
   PubMed Web of Science ®Google Scholar
• Palosse-Cantaloube L, Hurault-Delarue C, Beau A-B, et al. Risk of infections during the first year of life after in utero exposure to drugs acting on immunity: a population-based cohort study. Pharmacol Res. 2016 nov;113(Pt A):557–562.
   PubMed Web of Science ®Google Scholar
• Beau A-B, Didier A, Hurault-Delarue C, et al. Prescription of asthma medications before and during pregnancy in France: an observational drug study using the EFEMERIS database. J Asthma off J Assoc Care Asthma. Avr 2017;54(3):258–264.
   PubMed Web of Science ®Google Scholar
• Montastruc F, Salvo F, Arnaud M, et al. Signal of Gastrointestinal congenital malformations with antipsychotics after minimising competition bias: a disproportionality analysis using data from vigibase(®). Drug Saf. 2016 juill;39(7):689–696.
   PubMed Web of Science ®Google Scholar
• Vermes G, Á M, Czeizel AE, et al. Maternal factors in the origin of isolated oesophageal atresia: a population-based case-control study. Birt Defects Res A Clin Mol Teratol. 2015 sept;103(9):804–813.
   PubMed Web of Science ®Google Scholar
• Beau AB, Hurault-Delarue C, Vidal S, et al. Pandemic A/H1N1 influenza vaccination during pregnancy: a comparative study using the EFEMERIS database. Vaccine. 2014 mars 5;32(11):1254–1258.
   PubMed Web of Science ®Google Scholar
• Beau A-B, Montastruc J-L, Lacroix I, et al. Atropinic burden of drugs during pregnancy and psychological development of children: a cohort study in the EFEMERIS database. Br J Clin Pharmacol. 2016 Aug;82(2):478–486.
   Web of Science ®Google Scholar
• Facts |Birth Defects |NCBDDD |CDC [Internet]. [cité 2017 mai 24]. Disponible sur: https://www.cdc.gov/ncbddd/birthdefects/facts.html
   Google Scholar
• De Santis M, Straface G, Carducci B, et al. Risk of drug-induced congenital defects. Eur J Obstet Gynecol Reprod Biol. 2004 nov 10;117(1):10–19.
   PubMed Web of Science ®Google Scholar
• Mitchell AA Studies of drug-induced birth defects. In: MPH BLSM, MSCE SEKM, PHARMD SH, éditeurs. Pharmacoepidemiology [Internet]. Wiley-Blackwell; 2012 [cité 24 mai 2017]. p. 487–504. Disponible sur: http://onlinelibrary.wiley.com/doi/10.1002/9781119959946.ch28/summary
   Google Scholar
• As R. Adverse drug events: identification and attribution. Drug Intell Clin Pharm. 1987 nov;21(11):915–920.
   PubMedGoogle Scholar
• Vg M, Sg M. Glucocorticoids and fetal programming part 1: outcomes. Nat Rev Endocrinol. 2014 juill;10(7):391–402.
   PubMed Web of Science ®Google Scholar
• Moisiadis VG, Matthews SG. Glucocorticoids and fetal programming part 2: mechanisms. Nat Rev Endocrinol. 2014 juill;10(7):403–411.
   PubMed Web of Science ®Google Scholar
• Charlton RA, Neville AJ, Jordan S, et al. Healthcare databases in Europe for studying medicine use and safety during pregnancy. Pharmacoepidemiol Drug Saf. juin. 2014;23(6):586–594.
   PubMed Web of Science ®Google Scholar
• De Jonge L, Garne E, Gini R, et al. Improving information on maternal medication use by linking prescription data to congenital anomaly registers: a EUROmediCAT study. Drug Saf. Nov 2015;38(11):1083–1093.
   PubMed Web of Science ®Google Scholar
• EUROmediCAT [Internet]. [ cité 2017 juin 28]. Disponible sur: http://www.euromedicat.eu/home
   Google Scholar
• Graner S, Svensson T, A-B B, et al. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. Bmj. 2017 févr 28;356:j629.
   PubMed Web of Science ®Google Scholar
• Hurault-Delarue C, Chouquet C, Savy N, et al. How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women? Pharmacoepidemiol Drug Saf. Juill. 2016;25(7):770–777.
   PubMed Web of Science ®Google Scholar
• Hurault-Delarue C, Chouquet C, Savy N, et al. Interest of the trajectory method for the evaluation of outcomes after in utero drug exposure: example of anxiolytics and hypnotics. Pharmacoepidemiol Drug Saf. 2017 mai;26(5):561–569.
   PubMed Web of Science ®Google Scholar
• Vigod SN, Gomes T, Wilton AS, et al. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. Bmj. 2015 mai 13;350:h2298.
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Hernán MA, Meyer K, et al. Case-crossover and case-time-control designs in birth defects epidemiology. Am J Epidemiol. 2003 août 15;158(4):385–391.
   PubMed Web of Science ®Google Scholar
• Brandlistuen RE, Ystrom E, Eberhard-Gran M, et al. Behavioural effects of fetal antidepressant exposure in a Norwegian cohort of discordant siblings. Int J Epidemiol. 2015 août;44(4):1397–1407.
   PubMed Web of Science ®Google Scholar
• Mmhj VG, Ialm VR, Ltw DJ-VEB, et al. Teratogenic mechanisms associated with prenatal medication exposure. Therapie. 2014 févr;69(1):13–24.
   PubMed Web of Science ®Google Scholar
• Laurent L, Huang C, Ernest SR, et al. In utero exposure to venlafaxine, a serotonin-norepinephrine reuptake inhibitor, increases cardiac anomalies and alters placental and heart serotonin signaling in the rat. Birt Defects Res A Clin Mol Teratol. 2016 déc;106(12):1044–1055.
   PubMed Web of Science ®Google Scholar
• Battista M-C, Boutin M, Venne P, et al. Maternal inhaled fluticasone propionate intake during pregnancy is detected in neonatal cord blood. Bioanalysis. 2016 juin 28.
   PubMed Web of Science ®Google Scholar